variable dose
Recently Published Documents


TOTAL DOCUMENTS

107
(FIVE YEARS 15)

H-INDEX

18
(FIVE YEARS 0)

2021 ◽  
Vol 50 (1) ◽  
pp. 445-445
Author(s):  
Melanie Condeni ◽  
Kyle Weant ◽  
Ron Neyens ◽  
Evert Eriksson ◽  
Todd Miano

2021 ◽  
Author(s):  
Liliana Marii ◽  
◽  
Larisa Andronic ◽  
Svetlana Smerea ◽  
Natalia Balasova ◽  
...  

Studying the particularities of manifestation of defensive indicators – POX and PPO in case of in-fection with 2 types of viruses of different virus-host combinations (sensitive, tolerant, resistant) was per-formed in basis of analysis of variance. The obtained results denote a significant contribution of all ana-lyzed factors in the variability of PPO and POX indices, the major contribution returning to the genotype, followed by viral infection, the type of viral infection with a variable dose of contribution depending on the applied matrix. The PPO index expressed a higher specificity of the genotype response depending on the virus applied compared to POX. At the same time, it was found that TAV had a higher contribution in the variability of POX and PPO, compared to TMV.


2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 205-206
Author(s):  
Kenneth Lam ◽  
Siqi Gan ◽  
Bocheng Jing ◽  
Brian Nguyen ◽  
Sei Lee

Abstract The American Medical Directors Association and the American Diabetes Association discourage the use of sliding scale insulin (SSI) in nursing home residents with diabetes due to its association with hypoglycemia, hyperglycemia, nursing burden, and patient discomfort. However, prevalence of SSI use is unclear. We used Veterans Affairs (VA) data from October 2013 to September 2016 to determine the weekly prevalence of SSI among 22,847 veterans with diabetes admitted to VA nursing homes (NHs). Average age was 75.3 (SD 8.3) years, mean A1c was 7.3% (SD 1.6%) and 57% were admitted from hospital. We first identified residents receiving any short-acting insulin. We then classified short-acting insulin use into three mutually exclusive regimens: (1) fixed scheduled doses, (2) SSI, defined as a variable dose of short-acting insulin without a concurrent fixed dose or (3) bolus with correction (BWC), defined as a variable dose given concurrently with a fixed dose that day. During the first week of NH admission, 64.7% of residents with diabetes received no short-acting insulin, 7.4% received fixed scheduled doses, 6.3% received BWC and 21.4% were on SSI. At week 12, the prevalence of fixed dose and BWC regimens was unchanged from baseline (fixed dose = 8.4%; BWC = 7.0%). In contrast, the prevalence of SSI decreased weekly to 15.8% (p for linear trend < 0.0001). Although SSI prevalence decreased from week 1 to week 12, 51% of residents on short-acting insulin were still using SSI in their 12th week of their NH stay.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Guy Garty ◽  
Yanping Xu ◽  
Gary W. Johnson ◽  
Lubomir B. Smilenov ◽  
Simon K. Joseph ◽  
...  

AbstractIn the long term, 137Cs is probably the most biologically important agent released in many accidental (or malicious) radiation disasters. It can enter the food chain, and be consumed, or, if present in the environment (e.g. from fallout), can provide external irradiation over prolonged times. In either case, due to the high penetration of the energetic γ rays emitted by 137Cs, the individual will be exposed to a low dose rate, uniform, whole body, irradiation. The VADER (VAriable Dose-rate External 137Cs irradiatoR) allows modeling these exposures, bypassing many of the problems inherent in internal emitter studies. Making use of discarded 137Cs brachytherapy seeds, the VADER can provide varying low dose rate irradiations at dose rates of 0.1 to 1.2 Gy/day. The VADER includes a mouse “hotel”, designed to allow long term simultaneous residency of up to 15 mice. Two source platters containing ~ 250 mCi each of 137Cs brachytherapy seeds are mounted above and below the “hotel” and can be moved under computer control to provide constant low dose rate or a varying dose rate mimicking 137Cs biokinetics in mouse or man. We present the VADER design and characterization of its performance over 18 months of use.


Sign in / Sign up

Export Citation Format

Share Document